Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cisplatin is a platinum-based chemotherapy drug classified as an alkylating agent. It works by binding to and cross-linking DNA, forming DNA adducts that disrupt DNA replication and transcription, ultimately leading to cell cycle arrest and apoptosis in rapidly dividing cells such as cancer cells[1][4][5][6]. Cisplatin is used alone or in combination with other therapies—including radiotherapy—to treat various solid tumors, including cancers of the bladder, ovary, testicle, head and neck, lung, cervix, esophagus, brain (including neuroblastoma), mesothelioma, sarcomas, lymphomas, and germ cell tumors[2][3][4][5]. When combined with radiotherapy (cisplatin + radiotherapy), it acts as a radiosensitizer—enhancing the effect of radiation on tumor cells. The combination is commonly used for locally advanced cancers such as head and neck squamous cell carcinoma or cervical cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cisplatin + radiotherapy.